News for Apellis Pharmaceuticals, Inc. (APLS)

**media[633082]**

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

U.S. stock futures were higher this morning, with the Dow futures gaining over 300 points on Wednesday. Shares of Sarepta Therapeutics, Inc. SRPT fell sharply ...

**media[617224]**

WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. ( APLS) today announced that the company will participate in the following May

WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. ( APLS) today announced that the company will host a conference call and webc

We recently published a list of 11 Oversold NASDAQ Stocks to Buy Right Now. In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

In a recent evaluation, Cantor Fitzgerald has initiated coverage on Apellis Pharmaceuticals, Inc. (APLS), assigning an Overweight rating along with a price targ

We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against other Guru stocks to invest in. Wall Street seems to be breathing a little easier after the initial panic over […]

We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc. (APLS) has announced a significant addition to its Board of Directors with the appointment of Craig Wheeler. Wheeler, who brings o

Apellis Pharmaceuticals (APLS) appoints Craig Wheeler to its Board of Directors, effective immediately. Craig Wheeler has extensive experience in the bi

Summary On April 21, 2025, Apellis Pharmaceuticals Inc (APLS) announced the appointment of Craig Wheeler, founder and CEO of Headwaters Biotech Advisors, to its

WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. ( APLS) today announced that Craig Wheeler, founder and chief executive offic

**media[600295]**

Bank of America has adjusted its price target for Apellis Pharmaceuticals (APLS), bringing it down to $41 from the previous $44. Despite this revision, the inve

Gene therapy is a medical approach that entails changing or modifying genes to treat or prevent disease.

On March 24, 2025, EcoR1 Capital, LLC (Trades, Portfolio), a prominent investment firm, made a strategic move by increasing its stake in Zymeworks Inc (ZYME). T